These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10282682)

  • 21. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
    Summers KH; Szeinbach SL
    Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacy and therapeutics committee review of the parenteral cephalosporins.
    Phelps MR; Godwin HN
    Am J Hosp Pharm; 1978 Jan; 35(1):73-5. PubMed ID: 623122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the microbiology laboratory in guiding formulary decisions.
    Stratton CW
    Hosp Formul; 1988 Aug; 23(8):654-7. PubMed ID: 10312591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P&T Committee antibiotic cost considerations.
    Rinehart JR
    Hosp Formul; 1986 Aug; 21(8):857-9, 862-4. PubMed ID: 10277580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P & T Committee interview: Establishing and maintaining a dynamic formulary.
    Rostand S; Lazarus H
    Hosp Formul; 1988 Jan; 23(1):48-53. PubMed ID: 10285373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving an effective committee through reorganization: the Ohio State University Hospital's experience.
    Lewis RP; Moore TD
    Hosp Formul; 1991 Feb; 26(2):120-30. PubMed ID: 10109143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective reimbursement and DRGs: implications for formulary management.
    Enright SM
    Hosp Formul; 1983 Oct; 18(10):989-90, 999-1000. PubMed ID: 10310246
    [No Abstract]   [Full Text] [Related]  

  • 33. A multidisciplinary process to determine, communicate, and manage an antibiotic formulary.
    Cook AA; Sanchez ML
    Hosp Pharm; 1992 Oct; 27(10):867-9, 872-4, 882. PubMed ID: 10121423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of selective administration procedures in formulary maintenance.
    Quigley MA; Brown WM
    Hosp Pharm; 1981 Jul; 15(7):371-4, 378-80. PubMed ID: 10252001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy.
    Simon WA; Thompson L; Campbell S; Lantos RL
    Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total formulary review--the easy way.
    Chase K; Meyer JD; Kelly WN
    Hosp Pharm; 1984 Mar; 19(3):159-62. PubMed ID: 10265845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of an enteral products formulary.
    Durfee DD; Skinner-Domet VM
    Am J Hosp Pharm; 1984 Nov; 41(11):2352-4. PubMed ID: 6439034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An inside look at the UCLA P&T committee: how does it influence prescribing practices?
    Conolly ME
    Hosp Formul; 1986 Feb; 21(2):214-7. PubMed ID: 10275576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.